Abcam & Cancer Research UK join forces to accelerate cancer research

By Akshay Kedari  Date: 2020-07-09

Abcam & Cancer Research UK join forces to accelerate cancer research

Cancer Research UK, one of the world's biggest independent funder of cancer research, has recently joined forces with Abcam plc, a leading developer of life science tools and reagents, to commercialize and develop novel custom antibodies to strengthen cancer research.

According to the terms of this partnership, Abcam would create custom protein-based reagents to targets that are recognized by researchers at Cancer Research UK. These antibodies would support the ongoing research and progress the understanding of cancer biology. Moreover, it would potentially be the basis for novel therapies as well as help generate new diagnostic tools.

Upon request, Abcam would deliver unique antibodies created during the terms of the agreement to researchers funded by Cancer Research UK for a pre-determined span of exclusivity in correspondence to that antibody. 

Meanwhile, Abcam’s co-location in key technology spots throughout the world and global supply capability would allow these innovative reagents to be easily available across wider diagnostic and research development community.

Speaking on the move, Tony Hickson, CBO, Cancer Research UK, said that the company is thrilled to collaborate with Abcam to develop tools that scientists require to help advance their understanding of cancer and to extend its access to biological reagents.

Additionally, Abcam’s “end-to-end” expertise and antibody development capabilities would support works of numerous researchers with antibody reagents that could be utilized from the initial stages of R&D right to the clinical trials.

As for Dr. John Baker, SVP of Product Portfolio Innovation, Abcam, the company is delighted to partner with Cancer Research UK to strengthen research by scientist and offer them easy access to validated and specific reagents, thereby helping them attain future breakthrough quickly.

Prior to this news, Abcam had made headlines when it announced that it has purchased assets of oncology product portfolio and gene editing platform from Applied StemCell, Inc. (ASC) for life science diagnostic and research markets. 
 

Source credit: https://www.abcam.com/index.html?pageconfig=news&rid=17091

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Apple’s iPhone 13 production may take a hit due to global chip shortage

Apple’s iPhone 13 production may take a hit due to global chip shortage

By Akshay Kedari

Apple Inc. is likely to cut down production of its iPhone 13 model by approximately 10 million units on account of the global chip shortage. The American multinational technology company was previously expected to manufacture 90 million units of the ...

Israel's GoTo Global acquires German e-moped sharing platform emmy

Israel's GoTo Global acquires German e-moped sharing platform emmy

By Akshay Kedari

Israel-based multimodal vehicle sharing services provider GoTo Global Mobility Ltd. has reportedly acquired Germany’s shared e-scooter company emmy. The acquisition will allow GoTo Global to enter the German market as well as accelerate its Eur...

German airline Lufthansa adds four new planes to its A350 fleet

German airline Lufthansa adds four new planes to its A350 fleet

By Akshay Kedari

Deutsche Lufthansa AG recently revealed that it has agreed to take four new Airbus A350-900 long-haul passenger aircraft on lease, utilizing newer planes that are left grounded as airlines reorganize their balance sheets in the wake of the ...

Samsung fined USD 47 million by Dutch watchdog for price-fixing TVs

Samsung fined USD 47 million by Dutch watchdog for price-fixing TVs

By Akshay Kedari

South Korean electronics manufacturing giant Samsung Electronics Co. Ltd. has been charged a penalty of USD 46.9 million by the Dutch competition watchdog Authority for Consumers and Markets (ACM) for price-fixing practices in the Netherlands. The m...

TEA-Lab, MED-EL unveil the world's first multifunction hearing aid app

TEA-Lab, MED-EL unveil the world's first multifunction hearing aid app

By Akshay Kedari

Communication solution provider for cloud meetings Tencent Ethereal Audio Lab (TEA-Lab) together with Austria-quartered implantable hearing solutions leader MED-EL recently announced the launched a first-of-its-kind hearing aid app that incorporates ...